TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16356228
Drug: Conventional insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional insulin therapy (blood glucose less than 200 mg/dl)
Study: 12421159
Drug: 100% oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% oxygen (HBO treatment)
Study: 12421159
Drug: 10% oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% oxygen in nitrogen (hyperbaric normoxic placebo = sham treatment)
Study: 10601381
Drug: Beta-carotene (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (50 mg on alternate days, n = 19,939)
Study: 10601381
Drug: Beta-carotene (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (50 mg on alternate days) among smokers
Study: 6996113
Drug: Ferrous sulphate
Normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulphate (60 mg elemental iron)
Study: 6996113
Drug: Ferrous sulphate
Normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulphate (60 mg elemental iron) with riboflavin (6mg)
Study: 29358012
Drug: Once-daily eliglustat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily eliglustat dosing
Study: 29358012
Drug: Twice-daily eliglustat
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily eliglustat dosing
Study: 29358012
Drug: Once-daily and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily and twice-daily dosing
Study: 24673517
Drug: 10-g monofilament
Normalized name: lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10-g monofilament testing
Study: 15897788
Drug: Doxazosin 4
Normalized name: doxazosin 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin 4 mg/d
Study: 12370460
Drug: IV glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV glucose infusion
Study: 9843903
Drug: L-NAME 1
Normalized name: L
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NAME 1 microg. kg‐1. min‐1 for 30 min
Study: 9843903
Drug: L-NAME 5
Normalized name: L-5-HTP
DrugBank: Oxitriptan (DB02959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NAME 5 microg. kg‐1. min‐1 for 30 min
Study: 9843903
Drug: L-NAME 25
Normalized name: L
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NAME 25 microg. kg‐1. min‐1 for 30 min
Study: 7598322
Drug: Preservative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative therapy (QUART)
Study: 19857446
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose (LD) of vaccine
Study: 19857446
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose (HD) of vaccine
Study: 16918564
Drug: Cryotherapy combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryotherapy combined with intralesional triamcinolon injection
Study: 15579914
Drug: Tamoxifen 40
Normalized name: tamoxifen 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 40 mg/d
Study: 14658015
Drug: saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline infusion (control)
Study: 2663407
Drug: Paracetamol 650
Normalized name: Paracetamol 650 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 650 mg
Study: 31067329
Drug: ASP1707 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP1707 3 mg
Study: 31067329
Drug: ASP1707 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP1707 5 mg
Study: 31067329
Drug: ASP1707 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP1707 10 mg
Study: 31067329
Drug: ASP1707 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP1707 15 mg
Study: 7001687
Drug: Levamisole hydrochloride
Normalized name: Levamisole Hydrochloride
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levamisole hydrochloride (100 mg initially followed by 100 mg twice daily for 10 days)
Study: 7001687
Drug: Diethylcarbamazine citrate
Normalized name: Diethylcarbamazine Citrate
DrugBank: Diethylcarbamazine (DB00711)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diethylcarbamazine citrate (DEC) at 126 mg per kg body-weight
Study: 6341623
Drug: Intramuscular cephradine
Normalized name: Cephradine
DrugBank: Cefradine (DB01333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular cephradine followed by oral nitrofurantoin
Study: 6341623
Drug: Chlorhexidine disinfection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine disinfection followed by oral nitrofurantoin
Study: 29546292
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (1-g capsules containing ≥840 mg n-3 PUFAs as ethyl esters) with preoperative loading of 8-10 g over 2-5 days followed by 2 g/day until hospital discharge or postoperative day 10.
Study: 23019945
Drug: Jiangtang Xiaozhi
Normalized name: Jianghuang
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jiangtang Xiaozhi Capsule (JTXZC)
Study: 15914135
Drug: Mifepristone 200
Normalized name: mifepristone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 200 mg orally and Misoprostol 800 mcg vaginally
Study: 12074256
Drug: Almonds supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almonds supplement (76 kJ daily) for six months
Study: 10335000
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (inhaled budesonide 200‐400 microg twice daily + terbutaline 500‐1000 microg four times daily)
Study: 10335000
Drug: Budesonide (200‐400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (200‐400 microg twice daily)
Study: 10335000
Drug: Terbutaline (500‐1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (500‐1000 microg four times daily)
Study: 7769306
Drug: 480 mg
Normalized name: magaldrate 480 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 480 mg TMP-SMZ once a day
Study: 7769306
Drug: 960 mg
Normalized name: glycerin 960 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 960 mg TMP-SMZ once a day
Study: 373645
Drug: Symptomatic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic treatment alone
Study: 28522317
Drug: Progesterone receptor
Normalized name: Progesterone receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone receptor single nucleotide polymorphisms rs578029, rs471767, rs666553, rs503362, and rs500760
Study: 22108479
Drug: Pycnogenol® (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pycnogenol® (100 mg daily for 8 weeks)
Study: 19705494
Drug: Intramuscular diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular diclofenac (75 mg loading dose) and isotonic saline infusion (5-10 mL/kg per hour over 4 hours)
Study: 19705494
Drug: Placebo (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (500 mL isotonic saline infusion)
Study: 15070908
Drug: Levothyroxine (L-T4)
Normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine (L-T4) supplementation for 7 months in cohort 1 and 11 months in cohort 2.
Study: 12426264
Drug: Emergency treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emergency treatment for obstructive pulmonary disease
Study: 2178599
Drug: IM ephedrine
Normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IM ephedrine 25 mg
Study: 2178599
Drug: IM scopolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM scopolamine 0.1 mg
Study: 2178599
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg scopolamine
Study: 30595567
Drug: Losartan 25
Normalized name: LOSARTAN 25MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 25 mg daily
Study: 26178634
Drug: N-acetyl glucosamine
Normalized name: N-Acetyl Glucosamine 700 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl glucosamine (100 mg) and chondroitin sulfate (180 mg) daily for 24 weeks
Study: 22281781
Drug: Subacromial corticosteroid
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subacromial corticosteroid injections
Study: 21176307
Drug: goserelin 3.6
Normalized name: goserelin 3.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: goserelin 3.6 mg one month before ablation
Study: 3289357
Drug: Streptokinase (250,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase (250,000 IU intracoronary infusion over 90 minutes)
Study: 30744396
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy for insomnia (CBT-I)
Study: 30744396
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy for insomnia plus positive mood strategies (CBT-I+)
Study: 30744396
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy for insomnia (CBT-I) and CBT-I+
Study: 27997254
Drug: Guideline adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline adherence for COPD exacerbation treatment
Study: 25677074
Drug: STN 200
Normalized name: sTNF-R1
DrugBank: Pegsunercept (DB06611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: STN 200 mg b.i.d. + standard-exposure TAC (n=50)
Study: 25677074
Drug: STN 200
Normalized name: sTNF-R1
DrugBank: Pegsunercept (DB06611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: STN 200 mg b.i.d. + reduced-exposure TAC (n=52)
Study: 25677074
Drug: STN 300
Normalized name: sTNF-R1
DrugBank: Pegsunercept (DB06611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: STN 300 mg b.i.d. + reduced-exposure TAC (n=50)
Study: 25677074
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 1 g b.i.d. + standard-exposure TAC (control, n=52)
Study: 14616490
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream applied three times a week for 3 weeks
Study: 14616490
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream applied three times a week for 3 weeks
Study: 25578869
Drug: Oral metronomic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metronomic chemotherapy (daily celecoxib 200mg twice daily and weekly methotrexate 15mg/m²)
Study: 25578869
Drug: Intravenous single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous single agent cisplatin (75mg/m² every 3 weeks)
Study: 21903881
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g cocoa
Study: 21903881
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g cocoa
Study: 21903881
Drug: 13 g
Normalized name: UREA 13 g TOPICAL TABLET [CLEAN-UP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13 g cocoa
Study: 21903881
Drug: 26 g
Normalized name: Sunmark Lancet Thin 26 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 26 g cocoa
Study: 21903881
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 g cocoa)
Study: 17472022
Drug: perindopril 2
Normalized name: perindopril 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: perindopril 2 mg + indapamide 0.625 mg
Study: 17472022
Drug: placebo (substituted
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (substituted for perindopril 2 mg + indapamide 0.625 mg)
Study: 8460760
Drug: Diclofenac 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 1.0 mg.kg‐1
Study: 8460760
Drug: Papaveretum 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Papaveretum 0.2 mg.kg‐1
Study: 29415163
Drug: Bromocriptine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine administration
Study: 20471178
Drug: Aromatase inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitor (letrozole 2.5 mg)
Study: 20471178
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of aromatase inhibitor and estradiol (75 μg/24 h)
Study: 10478767
Drug: Advanced color‐coded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advanced color‐coded duplex sonography after spinal manipulation therapy
Study: 1292787
Drug: Fotemustine (FM)
DrugBank: Fotemustine (DB04106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fotemustine (FM) administered on days 1 and 8 alternating with Dacarbazine (DTIC) on days 15 and 16, followed by a 5-week rest period
Study: 30241119
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen treatment (HBO2) for four weeks in addition to routine therapy
Study: 30241119
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen treatment (HBO2)
Study: 19675319
Drug: Active medication
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active medication list alone
Study: 18768036
Drug: Carbohydrate-high-fat snack
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-high-fat snack (30 g CHO, 2 g protein, 20 g fat; 320 kcal)
Study: 18768036
Drug: Carbohydrate-low-fat snack
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-low-fat snack (30 g CHO, 2.5 g protein, 1.3 g fat; 138 kcal)
Study: 7718710
Drug: Synthetic salmon
Normalized name: Synthetic salmon calcitonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic salmon calcitonin (100 daily I.U. nasally administered) plus 500 mg of calcium per day
Study: 7718710
Drug: Calcium (1
Normalized name: hydroxyapatite 275 mg calcium (1,100 mg) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1 g per day)
Study: 6688772
Drug: Furosemide 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 0.5 mg/kg
Study: 31847830
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg daily for 90 days
Study: 26955673
Drug: Compound Tripterygium
Normalized name: Tripterygium wilfordii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Tripterygium wilfordii Hook F. (TwHF)
Study: 24768518
Drug: Dexmedetomidine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine at 0.5 μg/kg/h (LDA)
Study: 24768518
Drug: Dexmedetomidine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine at 1 μg/kg/h (HDA)
Study: 22033349
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TA) - 1g bolus followed by infusion at 200mg/h
Study: 22033349
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group - saline infusion
Study: 20840481
Drug: Tacrolimus BID
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus BID (twice-daily)
Study: 20840481
Drug: Tacrolimus QD
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus QD (once-daily)
Study: 17978109
Drug: Empiric antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empiric antibiotics to reduce chorioamnionitis-related perinatal HIV transmission
Study: 11970761
Drug: Denileukin diftitox
Normalized name: Denileukin diftitox
DrugBank: Denileukin diftitox (DB00004)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Denileukin diftitox 9 microg/kg/day or 18 microg/kg/day, administered intravenously over 15-60 minutes for 5 consecutive days, cycles every 21 days for a total of 8 cycles over 6 months.
Study: 10323055
Drug: NPH Insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH Insulin (20 to 40 units at bedtime)
Study: 10323055
Drug: Metformin (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (up to 3 grams) combined with Sulphonylureas
Study: 8225725
Drug: 2% topical
Normalized name: A/T/S 2% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% topical minoxidil solution
Study: 28646934
Drug: 2-minute delay
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-minute delay of peri-prostatic lidocaine injection
Study: 28646934
Drug: 10-minute delay
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-minute delay of peri-prostatic lidocaine injection
Study: 23816438
Drug: Control meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control meal (150 g cooked rice, sautéed beef menu containing 40 g raw beef, and 240 g vegetable)
Study: 20663999
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus famotidine 20 mg twice daily
Study: 20663999
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus lansoprazole 15 mg once daily
Study: 16431254
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of topical 1% testosterone gel (Testim) applied daily for 6 months
Study: 15203583
Drug: Raloxifene and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene and Atorvastatin (combined treatment)
Study: 9347199
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion alone
Study: 3690524
Drug: Oral medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral medroxyprogesterone acetate (MPA) 300 mg X 3 daily for 4 weeks and 500 mg X 2 weekly thereafter
Study: 3690524
Drug: Intramuscular (im)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (im) medroxyprogesterone acetate (MPA) 500 mg daily for 4 weeks and 500 mg X 2 weekly thereafter
Study: 3690524
Drug: Both oral
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both oral and im MPA
Study: 26954408
Drug: Naltrexone 32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 32 mg/d and Bupropion 360 mg/d
Study: 24345751
Drug: Bosutinib 500
Normalized name: bosutinib 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosutinib 500 mg per day
Study: 11193558
Drug: Ro64‐0796 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro64‐0796 75 mg once daily for six weeks
Study: 26171969
Drug: Realignment therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Realignment therapy using a valgus unloader knee brace plus bilateral neutral foot orthoses and motion control shoes for 12 weeks
Study: 23108692
Drug: Latrepirdine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latrepirdine (20 mg) administered orally 3 times daily for 26 weeks
Study: 23108692
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered orally 3 times daily for 26 weeks
Study: 19410462
Drug: Neoadjuvant endocrine
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant endocrine therapy with tamoxifen or anastrozole
Study: 11884295
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 2.5 mg/d, riboflavin 5 mg/d, B12 0.4 mg/d
Study: 11884295
Drug: Vitamin B6
Normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B6 50 mg/d (with folic acid treatment)
Study: 7770930
Drug: Recombinant interferon
Normalized name: Recombinant Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant interferon alpha‐2b (IFNa) 3 million units three times weekly for 6 months (group A)
Study: 348225
Drug: Salbutamol by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol by intermittent positive pressure ventilation (IPPV) 5 mg
Study: 348225
Drug: Salbutamol by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol by intermittent positive pressure ventilation (IPPV) 10 mg
Study: 31366975
Drug: Defibrotide infusion
Normalized name: defibrotide
DrugBank: Defibrotide (DB04932)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Defibrotide infusion (6.25 mg/kg)
Study: 9658386
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose sodium valproate for 3 months
Study: 7805426
Drug: Amoxycillin/clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin/clavulanic acid (500 mg three times daily)
Study: 2780100
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g ceftriaxone (group I)
Study: 2780100
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g ceftriaxone (group II)
Study: 2780100
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g ceftriaxone in peritonitis (group III)
Study: 2780100
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g ceftriaxone in peritonitis (group IV)
Study: 3141887
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g ceftriaxone
Study: 3141887
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g ceftriaxone
Study: 24890861
Drug: Implants with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants with dehiscence defect
Study: 24890861
Drug: Implants with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants with intrabony defect
Study: 24890861
Drug: Implants without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implants without defect
Study: 24890861
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of bBL between implants with and without defect
Study: 23801020
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy with a defibrillator (CRT-D)
Study: 19781431
Drug: L‐N(G)‐monomethyl‐arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐N(G)‐monomethyl‐arginine
Study: 19781431
Drug: Norepinephrine dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine dose
Study: 10713296
Drug: Saccharin (23.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saccharin (23.7 mg)
Study: 9377617
Drug: Tamsulosin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (0.4 mg/d for 7 days followed by 0.8 mg/d for 7 days)
Study: 31402223
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL 0.5% plain bupivacaine (100 mg) plus 20 mL liposomal bupivacaine (266 mg)